TrypsiNNex® 0.5 MU

The animal-free, recombinant TrypsiNNex® sequence is identical to porcine Trypsin and can be used as a direct replacement when converting to animal-free manufacturing. TrypsiNNex® is expressed in E. coli as an inactive product. The trypsin remains inactivated during both the upstream and downstream manufacturing process, minimizing the level of auto degradation before final stabilization and packaging, thereby preserving a high content of β-trypsin.

Trypsin has intrinsic autolytic activity and is degraded in steps, where β-trypsin is converted into α-trypsin through proteolytic cleavage (red scissors).

This process continues until the trypsin is inactivated. Intermediate forms such as Ψ-trypsin display unspecific activity, which is undesirable. Thus, a high β-trypsin content is a quality indicator that ensures consistent activity and high specificity.

TrypsiNNex® has a measured β-trypsin of typically well above the minimum specifications at 70% ensuring a high activity and consistent proteolytic pattern, which is critical when processing precursor proteins, such as pro-insulin.

Enzymatic activity*: >333.000 USP units/ml

Product purity : ≥ 90 % (α- and β-trypsin)

β-trypsin content: ≥ 70%

Protein content: 55-85 mg/mL

Formulation: 10 mM HCl, 20 mM CaCl2

Bioburden (Microbial Count): ≤ 10 CFU/mL

Stability: 36 months at –20ºC ±5ºC


*Alternative units / USP units

1 Chromozym TRY Unit: 21 USP Units

  • Certificate of analysis
  • ISO 9001, 14001, 45001 certificates for Novo Nordisk Pharmatech’s management systems
  • TrypsiNNex® user guide
  • Quality statements: Origin/TSE, impurities, stability, primary packaging, manufacturing, etc.
  • Supplier questionnaire
  • SDS
  • EcoVadis Sustainability report 
  • Novo Nordisk Pharmatech’s quality system meets DS/EN ISO 9001 and Novo Nordisk Pharmatech’s environmental systems meet DS/EN ISO 14001 and 45001.
  • TrypsiNNex® is manufactured in accordance with GMP as defined by Novo Nordisk Pharmatech based on applicable chapters in DS/EN ISO 9001 and IPEC GMP guideline for excipients (current version).
  • TrysiNNex® follows relevant recommendations of USP, chapter <1043> on ancillary materials for cells, gene, and tissue engineered products and Ph.Eur.,
    chapter <5.2.12> on raw materials of biological origin for the production of cell-based and gene therapy medicinal products.
  • TrypsiNNex® is produced by recombinant microbial expression in E.coli. No ingredients of animal origin are used in the cell banking and manufacturing process.
  • TrypsiNNex® is antibiotic-free, both in production facilities and on a cell bank level.
  • TrypsiNNex® is animal-free meaning it is TSE compliant

Storage and transportation 

TrypsiNNex® is shipped on dry ice.

TrypsiNNex® should be stored at ­‑20°C ±5ºC immediately upon arrival.

Please contact us for information on storage and handling after dilution.


Trypsin inhibitors

If trypsin inhibitors are needed, these may be possible to use:

  • Serum (beta 2 macroglobulin) 
  • Soybean Trypsin Inhibitor

Trypsin Detection 

In Biopharmaceutical production, detection of raw material is necessary: 

  • Incoming testing of TrypsiNNex® (e.g. identity, activity) 
  • Detection of residual raw material in the finished product (LOQ for HPLC-based purity measurement)

For support on incoming quality testing, please contact us. 

Although there are no specific regulatory guidelines at this time to specify allowable amounts of residual Trypsin or Collagenase, these are still considered process residuals and potential product contaminants, and thus should be assessed as part of an overall risk mitigation strategy. 

Explore more about TrypsiNNex®